(UroToday.com) Nivolumab plus ipilimumab and immunotherapy/vascular endothelial growth factor (VEGF) inhibitor combinations are now standard of care first-line treatment options for metastatic renal cell carcinoma (mRCC). However, there is limited head-to-head comparative evidence between these strategies in this evolving treatment landscape in mRCC: